他汀类药物被广泛认可用于治疗高胆固醇血症患者以减少心血管发病率和死亡率。最近，他们在阻碍肿瘤细胞增殖方面的多效性引起了广泛关注。先前的研究已经表明，他汀类药物可能有助于抑制癌症进展和微转移。然而，他汀类药物在乳腺癌中的益处尚未得出一致的结论。本次荟萃分析的目的是评估乳腺癌诊断后使用他汀类药物对乳腺癌复发和死亡率的影响。我们使用PubMed、Embase和Scopus进行系统文献检索，包括从2023年5月30日开始的相关文献。采用随机效应模型对危险比（HR）进行汇总。感兴趣的主要结果是乳腺癌复发的风险。次要结果包括乳腺癌特异性死亡率和全因死亡率。共纳入了15项研究，涉及156,448名患者，并进行了最终分析。他汀类药物使用组与非使用组的患者平均年龄分别为64.59岁和59.15岁。与非使用他汀类药物组比较，他汀类药物使用与乳腺癌复发的风险降低相关(HR 0.76, 95%CI: 0.67-0.87)。这一趋势在亲脂性他汀类药物使用组中相似(HR 0.73, 95%CI: 0.63-0.85)，但在亲水性他汀类药物使用组中不相似(HR 1.17, 95%CI: 0.82-1.68)。此外，他汀类药物使用组和非使用组在全因死亡率(HR 0.82, 95%CI: 0.66-1.02)和乳腺癌特异性死亡率(HR 0.87, 95%CI: 0.69-1.10)方面相当。然而，与非使用他汀类药物组相比，亲脂性他汀类药物在降低全因死亡率(HR 0.84, 95%CI: 0.75-0.93)和乳腺癌特异性死亡率(HR 0.85, 95%CI: 0.74-0.99)方面表现出优势。在乳腺癌患者中，诊断后使用他汀类药物可以降低乳腺癌复发的风险。此外，亲脂性他汀类药物还具有降低全因死亡率和乳腺癌特异性死亡率的额外优势。© 2023年作者。由牛津大学出版社代表欧洲心脏学会出版。

Statins are widely acknowledged for their application in patients with hypercholesterolemia to reduce cardiovascular morbidity and mortality. More recently, their potential to exert pleiotropic effects, particularly in impeding the proliferation of neoplastic cells, has attracted considerable attention. Prior studies have demonstrated that statins may mitigate cancer progression and micrometastasis. However, the benefits of statins in breast cancer have been inconclusive.The aim of this meta-analysis was to evaluate the impact of statin use following a breast cancer diagnosis on breast cancer recurrence and mortality.We performed a systematic literature search using PubMed, Embase, and Scopus for relevant articles from inception until 30th May 2023. Hazard ratios (HR) were pooled using a random-effect model. The primary outcome of interest was the risk of breast cancer recurrence. The secondary outcomes included breast cancer-specific mortality and all-cause mortality.A total of 15 studies with 156,448 patients were included in the final analysis. The mean age of patients between statin users and non-users was 64.59 and 59.15 years, respectively. Statin use was associated with a reduction in the recurrence of breast cancer (HR 0.76, 95%CI: 0.67-0.87) compared with non-statin users. This trend was similar among lipophilic statin users (HR 0.73, 95%CI: 0.63-0.85) but not for hydrophilic statin users (HR 1.17, 95%CI: 0.82-1.68). Furthermore, all-cause mortality (HR 0.82, 95%CI: 0.66-1.02) and breast cancer mortality (HR 0.87, 95% CI: 0.69-1.10) were comparable between statin and non-statin users. However, lipophilic statins demonstrated a reduction in both all-cause mortality (HR 0.84, 95%CI: 0.75-0.93) and breast cancer mortality (HR 0.85, 95%CI: 0.74-0.99) compared to non-statin users.Among patients with breast cancer, statin use post-diagnosis decreases the risk of breast cancer recurrence. Furthermore, lipophilic statins exhibit an additional advantage of reducing both all-cause and breast cancer-specific mortality.© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.